Publication Details

Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas.

Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ. Clin Cancer Res. 2003; 9 (1): 59-67

Tumor hypoxia modifies treatment efficacy and promotes tumor progression. Here, we investigated the relationship between osteopontin (OPN), tumor pO(2), and prognosis in patients with head and neck squamous cell carcinomas (HNSCC).

PubMedID: 12538452